MedTrace Logo

GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake

NCT02598791 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-12-06

No results posted yet for this study

Summary

We aim to delineate the effects of separate and combined infusion of GIP and GLP-1 on food intake, appetite, bone health and fat metabolism in overweight/obese subjects.

Conditions

Interventions

OTHER

IIGI+GIP

Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia

OTHER

IIGI+GLP-1

glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia

OTHER

IIGI+NaCl (placebo)

i.v. NaCl during isoglycemia

OTHER

OGTT

50 g oral glucose tolerance test

OTHER

IIGI+GIP+GLP-1

i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Natasha C Bergmann, MD · Center for Diabetesresearch, Gentofte Hospital, University of Copenhagen, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2016-06-20
Completion
2016-06-20

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02598791 on ClinicalTrials.gov